Recursion Pharmaceuticals expanded its collaboration with Citeline to integrate real world data into its AI enabled ClinTech Platform. The partnership is aimed at refining clinical trial design and ...

Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: 25th ...

Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer ...

Recursion Pharmaceuticals (RXRX) closed at $3.32 in the latest trading session, marking a -2.06% move from the prior day. This change lagged the S&P 500's daily gain of 0.62%. Meanwhile, the Dow ...

While the advent of artificial intelligence (AI) has obviously changed the world, not every utilization of AI has necessarily ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $2.94, moving -6.67% from the previous trading session ...

Nvidia is looking to increase the adoption of AI by biotechnology companies, which could boost its shares, per Goldman Sachs.

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Event driven snapshot of Recursion Pharmaceuticals Recursion Pharmaceuticals (RXRX) shares have been drawing attention after ...

The technology sector is no longer asking what artificial intelligence can do for us. It is asking what AI can do for itself.

Now, it’s worth noting Stock Advisor’s total average return is 880 % — a market-crushing outperformance compared to 178% for ...

In this article, we explore the 10 Best Multibagger Penny Stocks to Invest In. Small-cap and penny stocks are often ...